News

The Other Malaria: Finding New Targets for a Vaccine Against Plasmodium vivax

Warhol style Plasmodium

A new report in PLOS Neglected Tropical Diseases describes the results of an international collaboration led by researchers at ISB and Seattle’s Center for Infectious Disease Research (CIDResearch). We used mass spectrometry-based proteomics to identify nearly 2,000 proteins present in Plasmodium vivax parasites, one of the Plasmodium species that cause the disease malaria in humans. The work was done on parasites dissected from mosquito salivary glands, parasites that were in the form that is transmitted from mosquitoes to humans. Because parasite proteins can potentially be recognized by the body’s immune system, the proteins we have identified are promising targets for new vaccines against malaria.

Read More

Recent Articles

  • Malaria Researchers’ Findings May Have Implications for Preventing Spread of Deadly Disease

    ISB researchers and their collaborators are using systems biology approaches to learn how the malaria parasite is able to transfer to humans via the bite of an infected mosquito. The information they have uncovered may help identify new ways to prevent people from contracting the deadly disease.

  • Andrea Varela-Stokes

    ISB’s Moritz Lab Lands NIH Grant to Study Lyme Disease

    ISB’s Moritz Lab has received research funding totaling nearly $525,000 from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health to develop “novel peptide based biomarkers for Lyme disease diagnostics.”

  • ISB’s proteomics research in the spotlight

    Microsoft Research recently deployed a video crew to come to ISB to speak with our researchers about proteomics and sharing peptide data. A story featuring the video was published on the Microsoft Research blog.